these two years as kevin mccarthy is going to have to deal with a very strong intransigent group of republicans. so this is just the first test for mccarthy, for the party, i mean, for everyone on capitol hill. i wonder, andrew, did mccarthy just demonstrate that he can be a leader? look, i mean, you know, it was ironic in the end that the people that were critical to him securing the speakership were the people who were in the never-kevin crowd, right? so a lot of the republicans who had been voting with him constantly gave him credit for having swayed them not to vote for him but to vote present so that you lower the threshold required to become speaker of the house. so, you know, in that sense it was a big victory for kevin mccarthy, but at the same time, as we ve been discussing here, he really did give away a lot of his power, a lot of the power that is inherent in the speakership. said more about the strategy in order to get there.
reporter: dr. sharon cohen has been studying alzheimer s drugs for 30 years and was part of the clinical trials for lecanemab. what she is talking about is amyloid originating abnormality. it can look like this or this. it s brain swelling or brain bleeding. know cohen says these types of side effects were mostly mild in the trial. we do know that lecanemab has a low rate of causing macro hemorrhage, not necessarily fatal, but a low rate, less than 1%. reporter: in the phase three clinical trial, there were seven deaths in the placebo group and six deaths in the lecanemab group. according to the investigators, though, none of the deaths were considered to be due to lecanemab or a.r.e.a. the new england journal of medicine recently published details of an additional death of ooh patient on the drug who had been given blood thinners, raising additional concerns. it s pretty hard to say lecanemab caused that when we re
reporter: they have become some of the most obstructionist. it give us the power of negation, the power of no. reporter: and antagonistic republican members on capitol hill. thed up with the ways of the swamp and fed up with leadership that fails us, telling us to vote along with a democrat agenda that is completely failing america. reporter: the house freedom caucus, a small but feisty group of republican rebels that have become a thorn stuck firmly in the side of republican leadership for nearly a decade. what i do not support is blindly supporting legislation that is critically flawed at its core because of, oh, we re in the minority. reporter: building a brand on challenging gop leaders, earning the various nicknames from their own party, like legislative terrorist, and a taliban 19. we re being told by our own republican leadership, well, it s 90% good, it s 90% tasty, 90% pure. there s only 10% poison and toxins in it but drink it
six deaths in the lecanemab group. according to the investigators, though, none of the deaths were due to the considered due to lecanemab or a. ria. the new england journal of medicine published details of the additional death of a patient on the drug who had been given blood thinners, raising additional concerns. it s hard to say lecanemab caused that when you re giving a drug that itself can cause significant pleading, however, the combination gives us pause. reporter: neurologist dr. richard isaacson agrees that while this drug shows promise it must come with caution. for example, avoiding blood thinners while taking the medication. i will prescribe this drug in the right person at the right dose and in a very carefully monitored way, but this drug is not for everyone. reporter: for jack the possibility of continuing to live a full life, spending quality time with all four children and all nine grandchildren, even for just a while longer, well, that is worth the risk. as f
were some adverse side effects associated with the drug lecanemab that we should point out. the most to come was infusion reactions. but they also saw on increase in brain edema, or swelling in the lecanemab group as well as the bone group, as well as a brain hemorrhage or bleeding. most of these are mild and asymptomatic and got better, however, brain bleeding and swelling can cause headache, confusion, visual changes, hospitalization, and have a longer term impact. when you compare the overall adverse effects that were serious, again, higher percentage in the lecanemab group, more people dropped out of the study to decide effects in the lecanemab group. really it is caution with the doctor, the patient in the family if this gets approved. and they really wear those risks and benefits. it may not be applicable to people with blood thinners because of the bleeding issue. because the side effects are very real. what is the process now? yeah, at this point i think that if it gets